The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Are CAR T-cell treatments likely to become available for acute myeloid leukemia?
Gail Roboz
September 28, 2020
During Blood Cancer Awareness Month, Know AML spoke to Gail Roboz, a world-leading doctor in acute myeloid leukemia. We asked, "Is there any prospect of CAR T-cell immunotherapy treatments becoming available for acute myeloid leukemia?" In this video, Gail describes how CAR T-cells have proved to be a promising modality for other hematological malignancies, before describing their use in clinical trials in acute myeloid leukemia and the results so far.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
